The Centers for Disease Control and Prevention (CDC) has provided guidelines on using Siga Technologies’ Tpoxx (tecovirimat) in treating monkeypox.
Boehringer Ingelheim’s monoclonal antibody inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for this indication.
We use cookies only to remember your preferences and provide better browsing experience. We do not sell user information. Here is our privacy policy.